MODEL VERDICT
Dianthus Therapeutics, Inc. (DNTH)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jun 5, 2026 | NEUTRAL | 0.16 | $80.51 | CURRENT | — |
| May 29, 2026 | NEUTRAL | 0.16 | $93.01 | CURRENT | — |
| May 22, 2026 | NEUTRAL | 0.16 | $86.48 | CURRENT | — |
| May 15, 2026 | NEUTRAL | 0.16 | $86.16 | CURRENT | — |
| May 8, 2026 | NEUTRAL | 0.16 | $86.66 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 4 industry peers | $1.35 | -98.3% | 4% | B | Data |
| Price / Sales 4 industry peers | $0.15 | -99.8% | 3% | B | Model Driven |
| Weighted Output Blended model output | $2.41 | -97.0% | 100% | 52 | SIGNIFICANTLY OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 1.95 | 2.06 | 0.32 | 3.97 | 1.38 |
| P/B Ratio | 1.95 | 2.06 | 0.32 | 3.97 | 1.38 |
| P/S Ratio | 213.81 | 116.48 | 3.69 | 764.98 | 315.34 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates DNTH's fair value at $2.41 vs the current price of $80.51, implying -97.0% downside potential. Model verdict: Significantly Overvalued. Confidence: 52/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $2.41 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%).
DNTH's current P/E of -19.2x compares to the industry median of 18.1x (3 peers in the group). This represents a -205.7% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
10 analysts cover DNTH with a consensus rating of Buy. The consensus price target is $111.91 (range: $55.00 — $145.00), implying +39.0% upside from the current price. Grade breakdown: Strong Buy (1), Buy (9), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 52/100, based on: data completeness (0), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for DNTH.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.